SCHEMBL5135247

SCHEMBL5135247

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccc([N+](=O)[O-])c(O)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
TSHR P16473 2/20 0.37
ALDH1A1 P00352 3/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
LMNA P02545 1/20 0.36
UBE2M P61081 1/20 0.35
DCUN1D1 Q96GG9 1/20 0.35
MAPT P10636 1/20 0.35
CYP19A1 P11511 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5075065 0.94 C5AR1 (0.43) C5AR1TSHRALDH1A1LMNAMAPT
SCHEMBL5137739 0.93 C5AR1 (0.43) C5AR1TSHRALDH1A1CYP1A2CYP2D6
SCHEMBL5072326 0.88 C5AR1 (0.41) C5AR1TSHRALDH1A1UBE2MDCUN1D1
SCHEMBL5135644 0.87 POLB (0.43) C5AR1TSHRALDH1A1MAPTKDM4E
SCHEMBL649709 0.85 C5AR1 (0.50) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL652036 0.85 C5AR1 (0.45) C5AR1TSHR
SCHEMBL648508 0.85 C5AR1 (0.50) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL652464 0.83 C5AR1 (0.44) C5AR1TSHR
SCHEMBL5135444 0.83 C5AR1 (0.47) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL651367 0.83 C5AR1 (0.45) C5AR1TSHRLMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed